Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida

Introduction: The new direct acting antivirals (DAA) have demonstrated low rates of adverse effects in controlled studies. However, real world-studies have disclosed emerging toxicities and drug-drug interactions in special populations. Methods: We conducted a retrospective review of HIV/HCV coinfec...

Full description

Bibliographic Details
Main Author: Jose Armando Gonzales Zamora
Format: Article
Language:English
Published: MDPI AG 2018-06-01
Series:Diseases
Subjects:
HIV
Online Access:http://www.mdpi.com/2079-9721/6/2/51
id doaj-f7f839c11f1044dfa3f39ae72cd52cf7
record_format Article
spelling doaj-f7f839c11f1044dfa3f39ae72cd52cf72020-11-25T02:26:20ZengMDPI AGDiseases2079-97212018-06-01625110.3390/diseases6020051diseases6020051Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, FloridaJose Armando Gonzales Zamora0Division of Infectious Diseases, Department of Medicine, University of Miami. Miller School of Medicine, Miami, FL 33136, USAIntroduction: The new direct acting antivirals (DAA) have demonstrated low rates of adverse effects in controlled studies. However, real world-studies have disclosed emerging toxicities and drug-drug interactions in special populations. Methods: We conducted a retrospective review of HIV/HCV coinfected patients who were treated with DAA at Jackson Memorial Hospital from 2014 to 2017. Our aim was to determine the adverse effects (AE) and factors that are associated with AE in HIV/HCV individuals who are treated with DAA. Results: There were 78 coinfected patients treated with DAA. AE that were secondary to DAA were reported by 21 (26.9%) patients. The most common AE were fatigue (47.6%), gastrointestinal symptoms (38.1%), anemia (14.3%), and headache (14.3%). In comparison with the rest of the study cohort, the patients who developed AE were more often Caucasian (33.3% vs. 10.5%, p = 0.017) and were more frequently treated with PrOD/Ribavirin (9.5% vs. 0%, p = 0.018). In terms of antiretroviral therapy (ART), there was a trend towards a more frequent use of TDF/FTC + NNRTI (33.3% vs. 14%, p = 0.055). Conclusions: These findings demonstrated good tolerability of DAAs in HIV/HCV coinfected patients. More real-world studies are needed to explore the variables that are associated with AE.http://www.mdpi.com/2079-9721/6/2/51adverse effectsHepatitis CHIVdirect acting antivirals
collection DOAJ
language English
format Article
sources DOAJ
author Jose Armando Gonzales Zamora
spellingShingle Jose Armando Gonzales Zamora
Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida
Diseases
adverse effects
Hepatitis C
HIV
direct acting antivirals
author_facet Jose Armando Gonzales Zamora
author_sort Jose Armando Gonzales Zamora
title Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida
title_short Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida
title_full Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida
title_fullStr Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida
title_full_unstemmed Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida
title_sort adverse effects of direct acting antivirals in hiv/hcv coinfected patients: a 4-year experience in miami, florida
publisher MDPI AG
series Diseases
issn 2079-9721
publishDate 2018-06-01
description Introduction: The new direct acting antivirals (DAA) have demonstrated low rates of adverse effects in controlled studies. However, real world-studies have disclosed emerging toxicities and drug-drug interactions in special populations. Methods: We conducted a retrospective review of HIV/HCV coinfected patients who were treated with DAA at Jackson Memorial Hospital from 2014 to 2017. Our aim was to determine the adverse effects (AE) and factors that are associated with AE in HIV/HCV individuals who are treated with DAA. Results: There were 78 coinfected patients treated with DAA. AE that were secondary to DAA were reported by 21 (26.9%) patients. The most common AE were fatigue (47.6%), gastrointestinal symptoms (38.1%), anemia (14.3%), and headache (14.3%). In comparison with the rest of the study cohort, the patients who developed AE were more often Caucasian (33.3% vs. 10.5%, p = 0.017) and were more frequently treated with PrOD/Ribavirin (9.5% vs. 0%, p = 0.018). In terms of antiretroviral therapy (ART), there was a trend towards a more frequent use of TDF/FTC + NNRTI (33.3% vs. 14%, p = 0.055). Conclusions: These findings demonstrated good tolerability of DAAs in HIV/HCV coinfected patients. More real-world studies are needed to explore the variables that are associated with AE.
topic adverse effects
Hepatitis C
HIV
direct acting antivirals
url http://www.mdpi.com/2079-9721/6/2/51
work_keys_str_mv AT josearmandogonzaleszamora adverseeffectsofdirectactingantiviralsinhivhcvcoinfectedpatientsa4yearexperienceinmiamiflorida
_version_ 1724847728969646080